目的 對(duì)比分析阿托伐他汀和瑞舒伐他汀所致藥品不良反應(yīng)，為臨床安全、合理選擇降脂藥提供參考。方法 采用回顧性分析的方法，對(duì)福州市長(zhǎng)樂區(qū)醫(yī)院2010—2019年上報(bào)的懷疑阿托伐他汀和瑞舒伐他汀所致不良反應(yīng)病例報(bào)告進(jìn)行對(duì)比分析。分別從患者一般情況、用藥情況、累及系統(tǒng)-器官損害、觀察指標(biāo)、不良反應(yīng)發(fā)生時(shí)間分布、及轉(zhuǎn)歸等方面進(jìn)行統(tǒng)計(jì)分析。結(jié)果 共篩選出89例阿托伐他汀所致的不良反應(yīng)報(bào)告、38例瑞舒伐他汀所致的不良反應(yīng)報(bào)告。阿托伐他汀以肝膽系統(tǒng)損害及骨骼肌系統(tǒng)損害多見，瑞舒伐他汀以肝膽系統(tǒng)及泌尿系統(tǒng)損害多見；阿托伐他汀涉及系統(tǒng)器官的不良反應(yīng)表現(xiàn)較多，阿托伐他汀和瑞舒伐他汀出現(xiàn)的LFTs>3×ULN、CK>10×ULN、SAMS的比較差異均無(wú)統(tǒng)計(jì)學(xué)意義。阿托伐他汀不良反應(yīng)多發(fā)生在用藥4～18 d，而瑞舒伐他汀多發(fā)生在5～20 d。阿托伐他汀與瑞舒伐他汀引起的不良反應(yīng)大部分為嚴(yán)重，經(jīng)采取相應(yīng)措施治療后易于好轉(zhuǎn)及治愈。結(jié)論 阿托伐他汀與瑞舒伐他汀引發(fā)的不良反應(yīng)臨床表現(xiàn)有所不同，但不良反應(yīng)發(fā)生時(shí)間及主要不良反應(yīng)觀察指標(biāo)相似，臨床用藥中應(yīng)當(dāng)根據(jù)實(shí)際情況進(jìn)行使用，以保障用藥安全。

Objective To compare and analyze the adverse drug reactions (ADR) caused by atorvastatin and rosuvastatin, and to provide a reference for clinical safety and reasonable choice of lipid-lowering drugs. Methods A retrospective analysis method was used to compare and analyze the case reports of suspected atorvastatin and rosuvastatin reported from 2010 to 2019 in Fuzhou Changle District Hospital. Statistical analysis was conducted in terms of patients' general condition, medication situation, systemorgan damage involved, observation indexes, time distribution of adverse reactions, and outcomes, etc. Results A total of 89 ADR reports suspected to be caused by atorvastatin and 38 ADR reports suspected to be caused by rosuvastatin were screened. Atorvastatin was more common in hepatobiliary system damage and skeletal muscle system damage, rosuvastatin was more common in hepatobiliary system damage and urinary system damage. Atorvastatin involved systemic organs with more adverse reactions, and the LFTS > 3×ULN, CK > 10×ULN and SAMs between atorvastatin and rosuvastatin showed no statistical significance. The ADR of atorvastatin mostly occurred 4 — 18 days after administration, while rosuvastatin mostly occurred 5 — 20 days after administration. Most of the ADRs caused by atorvastatin and rosuvastatin were severe, which were easy to improve and cure after treatment with appropriate measures. Conclusion The clinical manifestations of ADR caused by atorvastatin and rosuvastatin are different, but the occurrence time of ADR and the main adverse reaction observation indicators are similar. Clinical medication should be used according to actual conditions to ensure the safety of medication.

R972